BPC-157 vs CJC-1295

A synthetic 15-amino-acid pentadecapeptide derived from a protein in human gastric juice, widely researched for its effects on soft tissue healing, tendon repair, and gut integrity.

A synthetic GHRH analogue that stimulates pituitary growth hormone release. The short-acting form (no DAC) is typically paired with a ghrelin agonist like ipamorelin.

BPC-157 appears to upregulate growth hormone receptor expression, promote angiogenesis through VEGF pathways, and accelerate collagen reorganisation in damaged tissue. Animal models show effects on ligament, tendon, muscle, bone, and gastric mucosa repair.

CJC-1295 is a modified fragment of growth-hormone releasing hormone (residues 1–29) with four amino-acid substitutions that extend its half-life. The "no DAC" variant lacks the drug affinity complex tag and therefore has a shorter duration, producing physiological GH pulses.

250–500 mcg per day (research protocols)

100–200 mcg, 1–3 times daily (research protocols)

~4 hours (parenteral)

~30 minutes (no DAC); ~7 days (with DAC)

Subcutaneous, Intramuscular, Oral (stable form)

Subcutaneous

research-only

research-only

£16 · £3.2/mg via Peptides UK

£22 · £11/mg via Peptides UK